Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>

Ovarian Cancer Videos

Dr. Moore on Unanswered Questions With PARP Inhibitors in Ovarian Cancer
Dr. Moore on Unanswered Questions With PARP Inhibitors in Ovarian Cancer
Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, poses unanswered questions pertaining to the use and reuse of PARP inhibitors in ovarian cancer treatment.
Onclive TV   >   
PARP Inhibitor Mechanisms of Resistance
PARP Inhibitor Mechanisms of Resistance
Expert oncologists explore the mechanisms of resistance and effects of PARP inhibitors on later lines of chemotherapy.
Peer Exchange   >   Recent Developments in Management of Gynecologic Cancers
PARP Inhibitor Toxicity Management
PARP Inhibitor Toxicity Management
Panelists discuss how to manage PARP inhibitor toxicities, including gastrointestinal and hematologic adverse events and fatigue.
Peer Exchange   >   Recent Developments in Management of Gynecologic Cancers
Maintenance Therapy: PARP Inhibitor or Bevacizumab
Maintenance Therapy: PARP Inhibitor or Bevacizumab
Bradley Monk, MD, FACOG, FACS, leads a discussion on the meta-analysis comparing bevacizumab to PARP inhibitors as maintenance therapy in patients with ovarian cancer.
Peer Exchange   >   Recent Developments in Management of Gynecologic Cancers
Managing Platinum-Resistance and Recurrent Disease
Managing Platinum-Resistance and Recurrent Disease
A discussion on the treatment options for patients with recurrent ovarian cancer who are platinum sensitive or resistant.
Peer Exchange   >   Recent Developments in Management of Gynecologic Cancers
PARP Inhibitor Trial Updates
PARP Inhibitor Trial Updates
Key opinion leaders consider how the ongoing PARP inhibitor trial combination regimens are changing the treatment paradigm for patients with advanced ovarian cancer.
Peer Exchange   >   Recent Developments in Management of Gynecologic Cancers
Treatment Options for Patients with BRCA1/2
Treatment Options for Patients with BRCA1/2
Expert oncologists consider the use of olaparib and bevacizumab as maintenance therapy in patients with BRCA1/2-mutated ovarian cancer.
Peer Exchange   >   Recent Developments in Management of Gynecologic Cancers
Experts Discuss Highly Anticipated Study Results Across Tumor Types
Experts Discuss Highly Anticipated Study Results Across Tumor Types
OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.
Onclive TV   >   
Targeted Therapy Options for Advanced Ovarian Cancer
Targeted Therapy Options for Advanced Ovarian Cancer
Panelists discuss the targeted therapy options for newly diagnosed advanced ovarian cancer, with special consideration for the impact of bevacizumab following its frontline approval.
Peer Exchange   >   Recent Developments in Management of Gynecologic Cancers
Systemic Therapy Selection for Advanced EOC
Systemic Therapy Selection for Advanced EOC
Bradley Monk, MD, FACOG, FACS, leads a discussion on choosing systemic therapy for newly diagnosed advanced EOC, with consideration of the GOG 252, 114, and 172 studies.
Peer Exchange   >   Recent Developments in Management of Gynecologic Cancers
Next Page >>
Publication Bottom Border
Border Publication
 
x